Johnson & Johnson - Search News

FDA approves Johnson & Johnson’s nasal spray for depression

FDA approves Johnson & Johnson’s ketamine-derived nasal spray for depression as stand-alone treatment

The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult population.

U.S. News & World Report · 1d

FDA Approves Spravato Nasal Spray for Treatment-Resistant Depression

The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral antidepressants,

Popular Science · 1d

FDA approves first-of-its-kind nasal spray for severe depression

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD, and similar psychiatric conditions.

Johnson & Johnson, Q4

The Motley Fool · 1d

Johnson & Johnson Tops Q4 EPS Forecasts

Johnson & Johnson surpassed earnings expectations with strong sales, but it faces challenges ahead due to patent expirations.

SFGate · 1d

Johnson & Johnson: Q4 Earnings Snapshot

The average estimate of eight analysts surveyed by Zacks Investment Research was for earnings of $2 per share. The world's biggest maker of health care products posted revenue of $22.52 billion in the period,

Business Insider · 1d

Johnson & Johnson Q4 Profit Decreases, But Beats Estimates

Johnson & Johnson (JNJ) announced a profit for fourth quarter that decreased from last year but beat the Street estimates. The

Johnson & Johnson price target lowered to $165 from $170 at Raymond James

Raymond James lowered the firm’s price target on Johnson & Johnson to $165 from $170 and keeps an Outperform rating on the shares.

40m

Ben Johnson’s parting words for Lions doesn’t make betrayal sting any less

During his first press conference with his new employer on Wednesday, new Chicago Bears’ sideline leader had plenty of praise for an organization that he spent ...

1hon MSN

Eat macadamia nuts, prioritize sleep, exercise 1 hour per day and more practical tips I learned from Bryan Johnson at his 'Don't Die' summit

How far would you go to live a longer, healthier life? For tech entrepreneur Bryan Johnson, the answer is “as far as possible ...

Johnson & Johnson: Hold Rating Amid Mixed Performance and Future Uncertainties

Analyst Tim Anderson of Bank of America Securities reiterated a Hold rating on Johnson & Johnson (JNJ – Research Report), reducing the ...

What is success for the Caleb Williams-Ben Johnson duo in Year 1? | The Facility

Emmanuel Acho, LeSean McCoy, James Jones and Chase Daniel discuss what success looks like for the Caleb Williams-Ben Johnson duo in Year 1 with the Chicago Bears.

Jets X-Factor1h

Ex-NY Jets WR: No way Glenn will bring Rodgers back

One of the New York Jets' best wide receivers in franchise history thinks there is no way that new coach Aaron Glenn wants Aaron Rodgers.

Micah Parsons' brother rips Cowboys, Jerry Jones' Ben Johnson failure

Terrence Parsons Jr., the brother of Dallas Cowboys star Micah Parsons, teed off on the team after Jerry Jones failed to interview Ben Johnson.

PBS1h

California Republicans push back after Speaker Johnson’s threat to saddle wildfire aid with conditions

Some U.S. House Republicans in California are breaking with Speaker Mike Johnson over his suggestion that federal disaster aid be coupled with as-yet unspecified conditions on the wildfire-ravaged ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

FDA approves Johnson & Johnson’s nasal spray for depression

Johnson & Johnson, Q4

Related topics